Seragen Inc. (NASDAQ:SRGN) of Hopkinton, Mass., reportedearly data from its ongoing Phase I/II clinical trial ofDAB389IL-2, an interleukin-2 receptor targeted fusion toxin, atthe annual meeting of the American Association for CancerResearch in Orlando, Fla. The data showed early indications thatthe drug has anti-tumor activity in patients with non-Hodgkin'slymphoma, cutaneous T cell lymphoma or Hodgkin's disease.

(c) 1997 American Health Consultants. All rights reserved.